Valuation: Berkley Renewables Inc.

Market Cap 364K 326K 300K 272K 508K 34.6M 518K 3.58M 1.44M 18.2M 1.37M 1.34M 57.4M P/E 2016
4.22x
P/E 2017 -1.16x
Enterprise Value 5.13M 4.59M 4.22M 3.83M 7.15M 487M 7.29M 50.35M 20.21M 256M 19.24M 18.83M 807M EV / Sales 2016
3.53x
EV / Sales 2017 3.18x
Free-Float
90.7%
Yield 2016 *
-
Yield 2017 -
Manager TitleAgeSince
Chief Executive Officer 63 2002-06-19
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 63 -
Director/Board Member 66 2006-08-16
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 459K
+2.67%+2.14%+74.76%+30.38% 185B
+1.78%+1.69%+75.55%+78.02% 116B
+2.05%+1.54%+56.97%+31.96% 86.83B
-0.32%-1.26%-11.33%-2.80% 65.37B
+1.57%-0.26%+57.25%+3.78% 63.98B
+1.30%+1.29%+45.49%+47.95% 61.2B
+1.69%-0.43%+95.06%+73.08% 60.51B
+1.92%+1.48%+62.92%+12.95% 59.97B
+2.74%+3.08%+49.19%+33.86% 59.39B
Average +1.37%+0.93%+56.21%+34.35% 75.81B
Weighted average by Cap. +1.72%+1.25%+60.26%+36.46%

Financials

2016 2017
Net sales 1.03M 926K 852K 772K 1.44M 98.18M 1.47M 10.16M 4.08M 51.65M 3.88M 3.8M 163M 1.72M 1.54M 1.42M 1.29M 2.41M 164M 2.45M 16.94M 6.8M 86.15M 6.47M 6.34M 272M
Net income 173K 155K 142K 129K 241K 16.4M 245K 1.7M 681K 8.63M 648K 634K 27.2M -631K -565K -519K -471K -880K -59.87M -896K -6.19M -2.49M -31.49M -2.37M -2.32M -99.31M
Net Debt 2.92M 2.61M 2.4M 2.18M 4.07M 277M 4.15M 28.66M 11.5M 146M 10.95M 10.71M 459M 4.76M 4.26M 3.92M 3.55M 6.64M 452M 6.77M 46.77M 18.78M 238M 17.87M 17.49M 750M
Logo Berkley Renewables Inc.
Berkley Renewables Inc. is a Canada-based, growth-oriented diversified issuer also pursuing renewable energy opportunities, primarily in the solar energy sector. The Company is pursuing solar energy investments in Ontario, Canada. It is also engaged in developing autologous cell therapies to treat conditions linked to a deficit of healthy cells required for normal healing and function through RepliCel Life Sciences Inc. The Company's RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin and pattern baldness. The Company is also developing a proprietary injection device (RCI) for optimal clinical delivery. The Company is developing solar photovoltaic (PV) projects in Ontario, Canada, through its subsidiary, Solar Flow-Through General Partnership. Working with Solar Flow-Through, the Company has also developed a flow-through investment vehicle for investors to participate in Ontario's solar energy growth.
Employees
-